Ortoma AB Series B (ORT-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ortoma AB Series B (ORT-B) has a cash flow conversion efficiency ratio of -0.120x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-17.13 Million ≈ $-1.84 Million USD) by net assets (Skr142.72 Million ≈ $15.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View ORT-B share price today for real-time trading data and today's change.
Ortoma AB Series B - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Ortoma AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market value of Ortoma AB Series B for the company's overall valuation and market capitalisation.
Ortoma AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ortoma AB Series B ranked by their cash flow conversion efficiency. Also see ORT-B asset base for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phenom Resources Corp
V:PHNM
|
-0.007x |
|
Choice Development Inc
TW:9929
|
0.058x |
|
Senetas Corporation Ltd
AU:SEN
|
-0.024x |
|
Asphere Innovations Public Company Limited
BK:AS
|
0.054x |
|
Taiwan Benefit Co
TWO:3379
|
-0.128x |
|
Mtag Group Berhad
KLSE:0213
|
-0.016x |
|
CervoMed Inc.
NASDAQ:CRVO
|
-0.301x |
|
Penguen Gida Sanayi AS
IS:PENGD
|
0.009x |
Annual Cash Flow Conversion Efficiency for Ortoma AB Series B (2021–2025)
The table below shows the annual cash flow conversion efficiency of Ortoma AB Series B from 2021 to 2025. Review financial agility of Ortoma AB Series B to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr142.72 Million ≈ $15.36 Million |
Skr6.04 Million ≈ $649.78K |
0.042x | +131.12% |
| 2024-12-31 | Skr161.91 Million ≈ $17.42 Million |
Skr-22.01 Million ≈ $-2.37 Million |
-0.136x | -276.65% |
| 2023-12-31 | Skr173.54 Million ≈ $18.68 Million |
Skr13.35 Million ≈ $1.44 Million |
0.077x | +206.13% |
| 2022-12-31 | Skr114.29 Million ≈ $12.30 Million |
Skr-8.29 Million ≈ $-891.82K |
-0.073x | +37.94% |
| 2021-12-31 | Skr130.04 Million ≈ $13.99 Million |
Skr-15.19 Million ≈ $-1.63 Million |
-0.117x | -- |
About Ortoma AB Series B
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and … Read more